Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 3/20 | 0.50 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.49 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | MMP14 | P50281 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 6/20 | 0.40 |
| ▸ | IDH1 | O75874 | 2/20 | 0.39 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.38 |
| ▸ | QPCT | Q16769 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18860371 | 0.81 | FDPS (0.53) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL4241305 | 0.80 | FDPS (0.56) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL18713189 | 0.79 | FDPS (0.47) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL19504647 | 0.76 | FDPS (0.45) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL2697302 | 0.76 | CYP11B1 (0.50) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL13105208 | 0.75 | CYP11B1 (0.53) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL18682716 | 0.75 | FDPS (0.47) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL18713191 | 0.75 | FDPS (0.47) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL19004884 | 0.74 | FDPS (0.50) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL20940204 | 0.74 | FDPS (0.40) | FDPSGGPS1BTN3A1CA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10039773-B2 | Neridronic acid for treating arthritis | ANTECIP BIOVENTURES II LLC (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180110789-A1 | OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS | ANTECIP BIOVENTURES II LLC | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10039773-B2 | Neridronic acid for treating arthritis | SOST, NRDC, NMUR1 | FDPS 1337/4885GGPS1 674/4885BTN3A1 1740/4885 |
| US-20180110789-A1 | OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS | SOST, CSF1R, NFKBIA | FDPS 1333/4885GGPS1 992/4885BTN3A1 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.